Bibliography
- Lipton RB, Stewart WF, Diamond S, Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57
- Silberstein SD. Migraine. Lancet 2004;363:381-91
- Headache Classification Subcommittee of the International Headache Society. The International classification of headache disorders, 2nd edn. Cephalalgia 2004;24(Suppl 1):9-160
- Tietjen GE. Migraine and ischaemic heart disease and stroke: potential mechanisms and treatment implications. Cephalalgia 2007;27:981-7
- Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trend Pharmacol Sci 1992;12:307-11
- Martin VT, Goldstein JA. Evaluating the safety and tolerability profile of acute treatments for migraine. Am J Med 2005;118(Suppl 1):36S-44S
- Klein LS, Simpson RJ Jr, Stern R, Myocardial infarction following administration of sublingual ergotamine. Chest 1982;82:375-6
- Miihlberger V, Abbrederis K. Knapp E. Myocardial infarction during ergotamine medication in a young man with normal coronary arteries. Dtsch Med Wochenschr 1983;108:623-6
- Roithinger FX, Punzengruber C, Gremmel F, Myocardial infarction after chronic ergotamine abuse. Eur Heart J 1993;14:1579-81
- Pesaturo KA, Wooding FG. Modern management of the migraine headache. BMC Neurol 2010;10:18. doi: 10.1186/1471-2377-10-18
- Saito K, Markowitz S, Moskowitz MA. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 1988;24:732-7
- Dodick CW, Papademetriou V. Cardiovascular safety of triptans. Cephalalgia 2004;24:513-14
- Schurks M, Rist PM, Bigal ME, Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914
- Nichols DE, Nichols CD. Serotonin receptors. Chem Rev 2008;108:1614-41
- Erspamer V, Vialli M. Boll Soc Med-chir Pavia 1937;51:357
- Kaumann AJ, Frenken M, Posival H, Brown AM. Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors. Circulation 1994;90:1141-53
- Van den Berg EK, Schmitz JM, Benedict CR, Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation 1989;79:116-24
- Lamping KG, Kanatsuka H, Eastham CL, Nonuniform vasomotor responses of the coronary microcirculation to serotonin and vasopressin. Circ Res 1989;65:343-51
- Marcus ML, Chilian WM, Kanatsuka H, Understanding the coronary circulation through studies at the microvascular level. Circulation 1990;82:1-7
- Lamping KG, Marcus ML, Dole WP. Removal of the endothelium potentiates canine large coronary artery constrictor responses to 5-hydroxytryptamine in vivo. Circ Res 1985;57:46-54
- Woodman OL. Enhanced coronary vasoconstrictor responses to 5-hydroxytryptamine in the presence of a coronary artery stenosis in anaesthetized dogs. Br J Pharmacol 1990;100:153-7
- Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 1983;305:627-31
- Vanhoutte PM, Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 1989;80:1-9
- Golino P, Piscione F, Willerson JT, Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991;324:641-8
- Fanburg B, Lee S. A new role for an old molecule: serotonin as a mitogen. Am J Physiol 1997;272:L795-806
- Fargin A, Raymond JR, Lohse MJ, The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature 1988;335:358-60
- Hoyer D, Clarke DE, Fozaed JR, International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203
- Hargreaves RJ, Shepeard SL. Pathophysiology of migraine: new insight. Can J Neurol Sci 1999;26:S12-19
- De Vries P, Villalon CM, Saxena PR. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 1999;375:61-74
- Humphrey PPA, Feniuk W, Perren MJ, GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol 1988;94:1123-32
- Durham PL, Russo AF. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci 1999;19:3423-9
- Connor HE, Feniuk W, Humphrey PP. 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. Eur J Pharmacol 1989;161:91-4
- MassenVanDenBrink A, Reekers M, Bax WA, Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30
- Hillis WS, MacIntyre PD. Sumatriptan and chest pain. Lancet 1993;341:1564-5
- MacIntyre PD, Bhargava B, Hogg KJ, The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992;34:541-6
- MacIntyre PD, Bhargava B, Hogg KJ, Effect of subcutaneous sumatriptan, a selective 5-HT1 agonist, on the systemic, pulmonary and coronary circulation. Circulation 1993;87:401-5
- Van Zieweten PA, Blauw GJ, van Brummelen P. Pathophysiological relevance of Serotonin in cardiovascular disease. Prog Pharmacol Clin Pharmacol 1990;7:63-75
- Shimizu M, Hata K, Takaota H, Sumatripan provokes coronary artery spasm in patients with variant angina: possible involvement of serotonin 1B receptor. Int J Cardiol 2007;114:188-94
- McFadden EP, Clarke JG, Davies GJ, Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991;324:641-8
- Ross RN. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26
- Celermajer DS, Sorensen KE, Georgakopoulos D, Cigarette smoking is associated with dose related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88:2149-55
- Celermajer DS, Adams MR, Clarkson P, Passive smoking and impaired endothelium dependent arterial dilation in healthy young adults. N Engl J Med 1996;334:150-4
- Morrow JD, Frei B, Longmire AW, Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers – smoking as a cause of oxidative damage. N Engl J Med 1995;332:1198-203
- Barua RS, Ambrose JA, Eales-Reynolds LJ, Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation 2001;104:1905-10
- Chester AH, O'Neil GS, Yacoub MH. Sumatriptan and ischaemic heart disease. Lancet 1993;341:1419-20
- Ottervanger JP, Paalman HJA, Boxma GL, Stricker BHC. Transmural myocardial infarction with sumatriptan. Lancet 1993;341:861-2
- Weidmann B, Jansen W, Bojko P, Sumatriptan-induced myocardial infarction. Intensivmed 1994;31:353
- Kelly KM. Cardiac arrest following use of sumatriptan. Neurology 1995;45:1211-13
- O'Connor P, Gladstone P. Oral sumatriptan-associated transmural myocardial infarction. Neurology 1995;45:2274-6
- Mueller L, Gallagher RM, Ciervo CA. Vasospam-induced myocardial infarction with sumatriptan. Headache 1995;36:329-31
- Abbrescia VD, Pearlstein L, Kotler M. Sumatriptan-associated myocardial infarction: Report of case with attention to potential risk factors. J Am Osteopath Assoc 1997;97:162-4
- Main ML, Ramaswamy K, Andrews TC. Cardiac arrest and myocardial infarction immediately after sumatriptan injection. Ann Intern Med 1998;128:874
- Liston H, Bennett L, Usher B, Nappi J. The association of the combination of sumatriptan and methysergide in myocardial infarction in a premenopausal woman. Arch Intern Med 1999;159:511-13
- Hack JB. Oral sumatriptan-induced myocardial infarction. J Toxicol 2004;42:309-11
- Wasson S, Jayam VKS. Coronary vasospasm and myocardial infarction induced by oral sumatriptan. Clin Neuropharmacol 2004;27:198-200
- Tornoe K, Steffensen R. ST-segment elevation myocardial infarction following treatment with sumatriptan. Ugeskr Læger 2005;167:62-3
- Erbilen E, Ozhan H, Akdemir R, Yazici. A case of myocardial infarction with sumatriptan use. Pediatr Cardiol 2005;26:464-6
- Anghileri E, Toso V, Perini F. Acute myocardial infarction after sumatriptan administration for cluster headache. Neurol Sci 2006;26:456-9
- Weir RAP, Walters MR. Myocardial infarction after oral sumatriptan use in woman with normal coronary arteries. Am J Med 2007;120:e7-8
- Chalaupka FD. Acute myocardial infarction with sumatriptan: a case report and review of the literature. Headache 2009;49:762-4
- Finney DJ. The design and logic of a monitor of drug use. J Chronic Dis 1965;18:77-98
- Tepper SJ. Safety and rational use of the triptans. Med Clin North Am 2001;85:959-70
- Brown EG, Endersby CA, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: an overview. Eur Neurol 1991;31:339-44
- O'Quinn S, Davis RL, Gutterman DL, Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 1999;19:223-31
- Welch KM, Mathew NT, Stone P, Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000;20:687-95
- Dodick D, Lipton RB, Martin V, Triptan cardiovascular safety expert panel. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004;44:414-25
- Ottervanger JP, van Witsen TB, Valkenburg HA, Adverse reactions attributed to sumatriptan. A postmarketing study in general practice. Eur J Clin Pharmacol 1994;47:305-9
- Visser WH, Jaspers NMWH, de Vriend RHM, Ferrari MD. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996;16:554-9
- Ottervanger JP, Wilson JHP, Stricker BHC. Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature. Eur J Clin Pharmacol 1997;53:105-10
- Ottervanger JP, Valkenburg HA, Grobbee DE, Stricker BHC. Characteristics and determinants of sumatriptan-associated chest pain. Arch Neurol 1997;54:1387-92
- Hall GC, Brown MM, Jingping M, MacRae KD. Triptans in migraine. The risks of stroke, cardiovascular disease, and death in practice. Neurology 2004;62:563-8
- Velentgas P, Cole JA, Jingping MO, Severe vascular events in migraine patients. Headache 2004;44:642-51
- Glaxo Wellcome. Data on file. 1994
- Lewis PJ, Barrington SF, Marsden PK, A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography. Neurology 1997;48:1542-50
- Shoenen J. Acute migraine therapy – the newer drugs. Curr Opin Neurol 1997;10:237-43
- Miller D, Waters DD, Warnica W, Is variant angina the coronary manifestation of a generalized vasospastic disorder? N Engl J Med 1981;304:763-6
- Houghton LA, Foster JM, Whorwell PJ, Is chest pain after sumatriptan oesophageal in origin? Lancet 1994;344:985-6
- Fowler PA, Lacey LF, Thomas M, The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31:291-4
- Boska MD, Welch KM, Schultz L, Nelson J. Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects. Cephalalgia 2000;20:39-44
- Burstein R, Yarnitsky D, Goor-Aryeh I, An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-24
- Willett F, Curzen N, Adams J, Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan. BMJ 1992;304:1415
- Abrahamsen B, Christiansen, BD. Angina pectoris efter sumatriptan. Ugeskr Laeger 1992;154:3602-3
- Lippolis A, Castini D, Cirino D, Ornaghi M. Vasospasmo coronarico secondario a somministrazione sottocutanea di sumatriptan. G Ital Cardiol 1994;24:883-6
- Walton-Shirley M, Flowers K, Whiteside JH. Unstable angina pectoris associated with Imitrex therapy. Catheter Cardiovasc Diagn 1995;34:188
- Plosay JJ III, O'Connell TX. Acute coronary vasospasm resulting from sumatriptan administration in a patient with Raynaud's disease. Hosp Physician 2002;38:51-4
- Curtin T, Brooks AP, Roberts JA. Cardiorespiratory distress after sumatriptan given by injection. BMJ 1992;305:713-14
- Laine K, Raasakka T, Mantynen J, Saukko P. Fatal cardiac arrhythmia after oral sumatriptan. Headache 1999;39:511-12
- Morgan DR, Trimble M, McVeigh GE. Atrial fibrillation associated with sumatriptan. BMJ 2000;321:275
- Devadathan S, Gunning M. Atrial fibrillation following oral sumatriptan administration. Int J Cardiol 2006;107:112-13
- Davies MB, Krishnan A. Atrial fibrillation induced by sumatriptan – a case report and review. Cephalalgia 2005;25:863-1020 (page 924, poster F028)
- Sternfeld B, Stang P, Sidney S. Relationship of migraine headaches to experience of chest pain and subsequent risk for myocardial infarction. Neurology 1995;45:2135-42
- Kurth T, Graziano JM, Cook NR, Migraine and risk of cardiovascular disease in women. JAMA 2006;296:283-91
- Ahmed B, Bairey Merz CN, McClure C, WISE Study Group. Migraines, angiographic coronary artery disease and cardiovascular outcomes in women. Am J Med 2006;119:670-5
- Rose KM, Carson AP, Sanford CP, Migraine and other headaches. Association with Rose angina and coronary heart disease. Neurology 2004;63:2233-9
- Sarchielli P, Alberti A, Coppola F, Platelet-activating factor (PAF) in internal giugular venous blood of migraine without aura patients assessed during migraine attacks. Cephalalgia 2004;24:623-30
- Neunteufl T, Katzenschlager R, Hassan A, Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997;129:111-18
- Celermajer DS, Sorensen KE, Bull C, Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-74
- Gaeta G, De Michele M, Cuomo S, Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med 2000;334:840-6
- Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168-75
- Yetkin E, Ozisik H, Ozcan C, Decreased endothelium-dependent vasodilatation in patients with migraine: a new aspect to vascular pathophysiology of migraine. Coron Artery Dis 2006;17:29-33
- Vanmolkot FH, Van Bortel LM, de Hoon JN. Altered arterial function in migraine of recent onset. Neurology 2007;68:1563-70
- Yetkin E, Ozisik H, Ozcan C, Increased dilator response to nitrate and decreased flow-mediated dilatation in migraineurs. Headache 2007;47:104-10
- Tietjen GE, Herial NA, White L, Migraine and biomarkers of endothelial activation in young women. Stroke 2009;40:2977-82
- de Hoon JN, Smits P, Troost J, Forearm vascular response to nitric oxide and calcitonin gene-related peptide: comparison between migraine patients and control subjects. Cephalalgia 2006;26:56-63
- Vernieri F, Moro L, ltamura C, Patients with migraine with aura have increased flow mediated dilation. BMC Neurol 2010;10:18. doi: 10.1186/1471-2377-10-18
- Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc 2009;84:917-38
- Buntinx F, Knockaert D, Bruyninckx R, Chest pain in general practice or in hospital emergency department: is it the same? Fam Pract 2001;18:586-9
- Verdon F, Burnand B, Herzig L, Chest wall syndrome among primary care patients: a cohort study. BMC Fam Pract 2007;8:51-8
- Nilsson S, Scheike M, Engblom D, Chest pain and ischaemic heart disease in primary care. Br J Gen Pract 2003;53:378-82
- Kamineni R, Alpert JS. Acute coronary syndromes: initial evaluation and risk stratification. Prog Cardiovasc Dis 2004;46:379-92
- Miller CD, Lindsell CJ, Khandelwal S, Is the initial diagnostic impression of ‘noncardiac chest pain’ adequate to exclude cardiac disease? Ann Emerg Med 2004;44:565-74
- Evans RW, Martin V. Expert opinion: assessing cardiac risk prior to use of triptans. Headache 2000;40:599-602